# Study of Anti-tumour Effects and Safety of Prolarix™ in Hepatocellular Carcinoma

> **NCT00746590** · PHASE2 · TERMINATED · sponsor: **BTG International Inc.** · enrollment: 1 (actual)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DRUG:** Prolarix (tretazicar co-administered with caricotamide)

## Key facts

- **NCT ID:** NCT00746590
- **Lead sponsor:** BTG International Inc.
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-09
- **Primary completion:** 2009-06
- **Final completion:** 2009-08
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** Study terminated prematurely by sponsor for business reason. One patient was enrolled.
- **Last updated:** 2022-07-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00746590

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00746590, "Study of Anti-tumour Effects and Safety of Prolarix™ in Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT00746590. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*